| Literature DB >> 24198575 |
Abstract
Athletic activity is associated with an increased risk of sudden death for individuals with some congenital or acquired heart disorders. This review considers in particular the causes of death affecting athletes below 35 years of age. In this age group the largest proportion of deaths are caused by diseases with autosomal dominant inheritance such as hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, long QT-syndrome, and Marfan's syndrome. A policy of early cascade-screening of all first-degree relatives of patients with these disorders will therefore detect a substantial number of individuals at risk. A strictly regulated system with preparticipation screening of all athletes following a protocol pioneered in Italy, including school-age children, can also detect cases caused by sporadic new mutations and has been shown to reduce excess mortality among athletes substantially. Recommendations for screening procedure are reviewed. It is concluded that ECG screening ought to be part of preparticipation screening, but using criteria that do not cause too many false positives among athletes. One such suggested protocol will show positive in approximately 5% of screened individuals, among whom many will be screened for these diseases. On this point further research is needed to define what kind of false-positive and false-negative rate these new criteria result in. A less formal system based on cascade-screening of relatives, education of coaches about suspicious symptoms, and preparticipation questionnaires used by athletic clubs, has been associated over time with a sizeable reduction in sudden cardiac deaths among Swedish athletes, and thus appears to be worth implementing even for junior athletes not recommended for formal preparticipation screening. It is strongly argued that in families with autosomal dominant disorders the first screening of children should be carried out no later than 6 to 7 years of age.Entities:
Keywords: arrhythmogenic right ventricular cardiomyopathy; athletes; hypertrophic cardiomyopathy; screening; sudden death
Year: 2011 PMID: 24198575 PMCID: PMC3781887 DOI: 10.2147/OAJSM.S10675
Source DB: PubMed Journal: Open Access J Sports Med ISSN: 1179-1543
Sudden death in athletes during, or clearly associated with, athletic activity according to deaths reported to the Folksam insurance company 1998–2009 related to population insured (1.6 million)
| Age (years) | Number of deaths | Proportion of deaths per 100,000 insured |
|---|---|---|
| 14 or below | 5 | 0.31 per 100,000 |
| 15–19 | 9 | 0.56 per 100,000 |
| 20–24 | 3 | 0.19 per 100,000 |
| 25–29 | 2 | 0.05 per 100,000 |
| 30–34 | 6 | 0.09 per 100,000 |
| 35–65 and over | 43 | 0.38 per 100,000 and |
| All ages | 68 | 4,25 per 100,000 |
Notes: Total mortality equates an annual mortality rate of 0.35 per 100,000 insured athletes. Data from www.media.folksam.se/allt-farre-plotsliga-dodsfall-inom-idrotten.
Population-based annual mortality per 100,000 age-specific population in Sweden according to death certificates 1997–2003
| Cardiac diagnosis | 8- to 16-year age range | 17- to 30-year age range |
|---|---|---|
| HCM | 0.112 | 0.055 |
| DCM | 0.034 | 0.151 |
| Aortic stenosis | 0.042 | 0.009 |
| Coronary anomaly | 0.017 | 0.046 |
| Myocarditis | 0.024 | 0.008 |
| Marfan’s and/or aortic dissection | 0.048 | 0.290 |
| Sudden death normal heart (R960) | 0.050 | 0.114 |
| Combined mortality (including 142.8) | 0.327 | 0.689 |
Notes: Note that during this period ARVC did not have a separate diagnostic code; some unrecognized episodes have entered the R960 category, others might have been entered under DCM diagnostic code. A total of 2 cases over 8 years (0.016 per 100,000) have been entered under the code 142.8 as causing deaths in the 17–30 year age range, and might have been ARVC or other unspecified cardiomyopathy. Data from Östman-Smith I, Wettrell G, Keeton B, et al. Age-and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J. 2008;29(9):1160–1167.14
Abbreviations: ARVC, arrhythmogenic right ventricular cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy.
Population incidence of diseases commonly associated with sudden death
| Condition | Population incidence |
|---|---|
| HCM | 2/1000 |
| ARVC | 0.6–4/1000 |
| Coronary artery anomaly | <10/1000 |
| Wolff–Parkinson–White | 1.5–2.5/1000 |
| Patients with complex cardiac reconstruction or conduits | 0.85/1000 |
| Coarctation of the aorta | 0.25–0.39/1000 |
| Marfan’s syndrome | 0.2–0.33/1000 |
| Long QT syndrome | 0.2/1000 or more |
| valvar aortic stenosis | 0.09–0.24/1000 |
| Myocarditis | Unknown |
Abbreviations: ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, hypertrophic cardiomyopathy.
How to assess ECG abnormalities in the athlete
| Innocent physiological findings in athletes | Uncommon ECG abnormalities requiring further investigations |
|---|---|
| Sinus bradycardia 30–60/min | Left atrial enlargement |
| First-degree AV block (and transient A block Mobitz type I Wenchebach resolving with exercise) | Pathological Q-waves |
| Incomplete right bundle branch block (as long as there is not fixed splitting of the second heart sound on auscultation, and no abnormal T-wave inversion in precordial leads) | Inverted T-waves in leads other than III, avR and VI (V2 T-wave inversion can be accepted in prepubertal athletes) |
| Early repolarization (elevation of QR-ST junction >1 mm with up-sloping ST and usually concave shape) | ST-segment depression >1 mm |
| Isolated increase of QRS-voltages (without evidence of atrial hypertrophy or T-wave changes) | Complete right bundle branch block |
| Infrequent isolated unifocal ventricular ectopics disappearing at heart rates >110/min | Complete left bundle branch block |
| Left axis deviation | |
| Right axis deviation | |
| Nonspecific intraventricular conduction defect with QRS duration >110 ms | |
| Pre-excitation with PR interval <0.12 sec | |
| Prolonged QTc interval male: >440 msec, female: >460 msec | |
| Short QT-interval QTc < 320 msec | |
| Brugada-like ECG abnormalities with a ST-elevation ≥2 mm most prominent in right precordial leads characterized by high J-point and down sloping ST, with a “coved” or “saddleback” T-wave | |
| Frequent or polymorph ventricular ectopics | |
| Epsilon-waves in right precordial leads |
Abbreviation: AV, atrioventricular.
Figure 1The precordial ECG from a 12-year-old boy with hypertrophic obstructive cardiomyopathy, with syncope on exercise as presenting symptom. The only abnormality is that of large ECG-voltages, and a typical feature is the way R and S-waves from different leads are superimposed on each other at standard magnification with 10 mm/mV. The Sokolow–Lyon index is 5.8 mV, limb lead QRS-amplitude sum is 11.7 mV (fulfilling pediatric high risk criteria in HCM,36 and the 12-lead amplitude voltage sum is 31.5 mV, also in the high-risk territory.34
Figure 4Wolff–Parkinson–White syndrome with every third beat conducted with pre-excitation, and a typical delta-wave.
Figure 5Figure illustrating the age-profile at sudden death of patients with hypertrophic cardiomyopathy (HCM). A) Patients from a geographical cohort diagnosed with HCM in childhood (data from ref 14), and in B) a group of HCM patients of all ages from a tertiary referral center. Copyright © 1982. Reproduced with permission from Wolters Kluwer Health. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. 1982;65: 1388–1394.56 The dashed line indicates 14 year of age, the age recommended for initial pre-participation screening of active athletes. As is very obvious from this figure, a considerable amount of sudden deaths due to HCM occur before the age of 14.
Normal values of wall-to-cavity ratios
| Measure | Mean | 95% CI of mean | 95% prediction limit | 99% prediction limit |
|---|---|---|---|---|
| Age 6–10 yrs | 0.17 | 0.17–0.18 | 0.12–0.21 | 0.12–0.24 |
| Age 11–15 yrs | 0.18 | 0.17–0.19 | 0.13–0.23 | 0.12–0.25 |
| Age 16–35 yrs | 0.18 | 0.18–0.19 | 0.14–0.23 | 0.12–0.25 |
| Age 6–10 yrs | 0.17 | 0.16–0.17 | 0.13–0.20 | 0.13–0.21 |
| Age 11–15 yrs | 0.18 | 0.17–0.19 | 0.13–0.23 | 0.11–0.24 |
| Age 16–35 yrs | 0.18 | 0.17–0.19 | 0.13–0.22 | 0.12–0.24 |
| Age 6–10 yrs | 0.46 | 0.43–0.48 | 0.34–0.58 | 0.30–0.59 |
| Age 11–15 yrs | 0.48 | 0.46–0.50 | 0.36–0.61 | 0.32–0.62 |
| Age 16–35 yrs | 0.47 | 0.46–0.49 | 0.34–0.61 | 0.30–0.65 |
Note: Wall and cavity measurements as measured by long-axis M-mode echocardiography. Modified from Östman-Smith and Devlin.42
Abbreviations: SEPCAVR, diastolic septal thickness: diastolic left ventricular diameter; LVACVR, diastolic posterior left ventricular wall thickness: diastolic left ventricular diameter; SYSCAVR, systolic posterior left ventricular wall thickness: systolic left ventricular diameter.